IL259716A - Cancer treatment with a pi3k inhibitor in a patient previously identified as having a pik3ca mutation in ctdna - Google Patents
Cancer treatment with a pi3k inhibitor in a patient previously identified as having a pik3ca mutation in ctdnaInfo
- Publication number
- IL259716A IL259716A IL259716A IL25971618A IL259716A IL 259716 A IL259716 A IL 259716A IL 259716 A IL259716 A IL 259716A IL 25971618 A IL25971618 A IL 25971618A IL 259716 A IL259716 A IL 259716A
- Authority
- IL
- Israel
- Prior art keywords
- ctdna
- preselected
- cancer
- patient
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262620P | 2015-12-03 | 2015-12-03 | |
| PCT/IB2016/057208 WO2017093905A1 (en) | 2015-12-03 | 2016-11-30 | Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL259716A true IL259716A (en) | 2018-07-31 |
Family
ID=57517943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259716A IL259716A (en) | 2015-12-03 | 2018-05-30 | Cancer treatment with a pi3k inhibitor in a patient previously identified as having a pik3ca mutation in ctdna |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180353515A1 (enExample) |
| EP (1) | EP3383391A1 (enExample) |
| JP (1) | JP2018535997A (enExample) |
| KR (1) | KR20180084830A (enExample) |
| CN (1) | CN108366998A (enExample) |
| AU (1) | AU2016362683B2 (enExample) |
| CA (1) | CA3006419A1 (enExample) |
| HK (1) | HK1253737A1 (enExample) |
| IL (1) | IL259716A (enExample) |
| MX (1) | MX2018006777A (enExample) |
| RU (1) | RU2018123524A (enExample) |
| TW (1) | TW201722429A (enExample) |
| WO (1) | WO2017093905A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081549A1 (en) * | 2018-10-15 | 2020-04-23 | The Regents Of The University Of California | Methods and materials for assessing and treating cancer |
| CN116240287A (zh) * | 2023-01-17 | 2023-06-09 | 普洱市人民医院 | 基于循环肿瘤dna的乳腺癌标志物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048627B2 (en) | 2003-07-05 | 2011-11-01 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
| ES2537633T3 (es) | 2004-03-02 | 2015-06-10 | The Johns Hopkins University | Mutaciones del gen de PIK3CA en cánceres humanos |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20130317037A1 (en) * | 2010-11-16 | 2013-11-28 | Glaxosmithkline Intellectual Property Development Limited | Method of administration and treatment |
| EP2830621B1 (en) * | 2012-03-29 | 2020-10-21 | Novartis AG | Pharmaceutical diagnostic |
| EP3140427B1 (en) * | 2014-05-09 | 2020-10-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
-
2016
- 2016-11-30 RU RU2018123524A patent/RU2018123524A/ru not_active Application Discontinuation
- 2016-11-30 HK HK18112889.9A patent/HK1253737A1/zh unknown
- 2016-11-30 CA CA3006419A patent/CA3006419A1/en not_active Abandoned
- 2016-11-30 AU AU2016362683A patent/AU2016362683B2/en not_active Ceased
- 2016-11-30 JP JP2018528592A patent/JP2018535997A/ja active Pending
- 2016-11-30 MX MX2018006777A patent/MX2018006777A/es unknown
- 2016-11-30 US US15/779,873 patent/US20180353515A1/en not_active Abandoned
- 2016-11-30 KR KR1020187015263A patent/KR20180084830A/ko not_active Withdrawn
- 2016-11-30 EP EP16808813.6A patent/EP3383391A1/en not_active Withdrawn
- 2016-11-30 CN CN201680071092.XA patent/CN108366998A/zh active Pending
- 2016-11-30 WO PCT/IB2016/057208 patent/WO2017093905A1/en not_active Ceased
- 2016-12-02 TW TW105139803A patent/TW201722429A/zh unknown
-
2018
- 2018-05-30 IL IL259716A patent/IL259716A/en unknown
-
2019
- 2019-05-06 US US16/403,817 patent/US20200138824A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018123524A3 (enExample) | 2020-04-02 |
| HK1253737A1 (zh) | 2019-06-28 |
| TW201722429A (zh) | 2017-07-01 |
| MX2018006777A (es) | 2018-08-01 |
| AU2016362683B2 (en) | 2019-11-07 |
| US20200138824A1 (en) | 2020-05-07 |
| US20180353515A1 (en) | 2018-12-13 |
| KR20180084830A (ko) | 2018-07-25 |
| RU2018123524A (ru) | 2020-01-09 |
| CN108366998A (zh) | 2018-08-03 |
| WO2017093905A1 (en) | 2017-06-08 |
| CA3006419A1 (en) | 2017-06-08 |
| AU2016362683A1 (en) | 2018-05-31 |
| EP3383391A1 (en) | 2018-10-10 |
| JP2018535997A (ja) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251630A0 (en) | Combined therapy for use in cancer treatment | |
| IL258953A (en) | Dihydroimidazopyrazinone derivatives are useful for the treatment of cancer | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumors | |
| IL251905B (en) | Epilimod for use in the treatment of kidney cancer | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL251903A0 (en) | Epilimod for use in the treatment of colon cancer | |
| IL290251A (en) | Combination for effective treatment of metastatic cancer in patients | |
| PL3253208T3 (pl) | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL253533A0 (en) | Antihistamine for use in the treatment of breast cancer | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| HUE063428T2 (hu) | PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| ZA201902951B (en) | Nutritional composition for use in therapy of cancer patients | |
| IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
| KR20180084830A (ko) | ctDNA 내에 PIK3CA 돌연변이를 갖는 것으로 미리선택된 환자에서의 PI3K 억제제를 사용하는 암의 치료 | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| HK1261631B (en) | Combination for the effective treatment of metastatic cancer in patients | |
| GB201411111D0 (en) | bis-Pyridazine compounds and their use in treating cancer |